Clinical Trial Begins in U.S. for Cuban Lung Cancer Vaccine
New York, January 7 (RHC-Agencies)-- Roswell Park Cancer Institute in Buffalo, New York, has launched the first clinical trial in the United States to study the CIMAvax-EGF vaccine, a lung cancer treatment that was developed in Cuba. Roswell Park is then the only facility in the United States that offers this groundbreaking treatment.
CIMAvax-EGF vaccine is a lung cancer treatment that was developed by researchers with the Havana-based Molecular Immunology Center. The medication is a type of therapy that harnesses the body’s immune system to fight lung cancer.
The current trial is a Phase I out of II study of the CIMAvax-EGF vaccine in combination with the Anti-PD1 checkpoint inhibitor nivolumab in patients previously treated for advanced non-small cell lung cancer (NSCLC).
Commentaries
- Welcome to a new edition of the Jazz Place
- Minister Bruno Rodríguez: No Cuban family has escaped the impact of the US blockade
- RHC's national and international news stories Nov. 6
- Successive US administrations have sought to suffocate the Cuban economy for purely political reasons
- Washington’s hostile Cuba policy amounts to a fierce economic, trade and financial blockade
- RHC's national and international news stories Nov. 5
6707622
- Max: 19729
- yesterday: 3773
- today: 2580
- online: 116
- total: 6707622
Radio Habana Cuba © 2015 V 1.1.19
MAKE A COMMENT